Skip to main content
Caplight Logo









Santersus AG

Santersus AG

Private
ZurichHealthcare & Life Scienceshttps://santersus.com/

Last Round

Series A

Dec 1, 2025

Total Funding Raised

$810,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Santersus AG is a biotechnology company that develops NucleoCapture, a patent-protected extracorporeal blood purification technology designed to selectively remove cell-free DNA and neutrophil extracellular traps from patient blood to treat conditions such as sepsis, systemic lupus erythematosus, and organ transplant complications.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

therapeutic apheresisblood purificationNucleoCaptureextracorporeal therapyneutrophil extracellular trapsNETsblood cleansingcritical caresystemic inflammationmedical devicebiotechnologyorgan transplantationsepsis treatmentautoimmune diseaseFDA breakthrough device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Santersus AG Comparables

Compare Santersus AG with similar companies based on industry and business-model similarity.

Santersus AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Hemotune AG
82%
ExThera Medical
78%
Cytosorbents Corporation
74%

Santersus AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 1, 2025
SeedSep 1, 2021
SeedJul 1, 2021

Key People

Founding team and executive leadership

James Ladtkow

Chief Executive Officer

Executive Team

Santersus AG Investors

Notable investors and investment history

Santersus AG investors
InvestorRounds
Terumo VenturesSeries A
Norcliffe Capital LimitedSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2026

    Grew 38% QoQ, from 8 to 11 employees.

  • Aug 29, 2025

    NucleoCapture device granted Breakthrough Device Designation by the FDA.

Santersus AG Filings

Explore SEC and related filing metadata, where available.

Santersus AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Santersus AG's valuation, stock price, and market status.

Is Santersus AG a public or private company?

Santersus AG is a private company.

What is the current stock price of Santersus AG?

Santersus AG is a private company with no public stock price. No recent secondary market data is available.

How much is Santersus AG worth (valuation)?

Valuation information for Santersus AG is not publicly available.

Can I buy Santersus AG stock?

Santersus AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Santersus AG's last funding round?

Santersus AG's most recent funding round was Series A on December 1, 2025.

Who are the main investors in Santersus AG?

Key investors in Santersus AG include Norcliffe Capital Limited.

Will Santersus AG IPO soon?

No public IPO plans have been announced for Santersus AG.

How can I track Santersus AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Santersus AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersZurich
Employee Range9
Year Founded2017
Last FundingDec 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?